LivaNova (NASDAQ:LIVN) Upgraded by StockNews.com to “Strong-Buy” Rating

StockNews.com upgraded shares of LivaNova (NASDAQ:LIVN) from a buy rating to a strong-buy rating in a report released on Tuesday.

A number of other analysts also recently commented on the stock. The Goldman Sachs Group started coverage on shares of LivaNova in a report on Friday, October 4th. They issued a “buy” rating and a $65.00 target price on the stock. Baird R W upgraded shares of LivaNova from a “hold” rating to a “strong-buy” rating in a report on Tuesday, September 17th. Mizuho decreased their price objective on shares of LivaNova from $80.00 to $70.00 and set an “outperform” rating for the company in a report on Thursday, October 31st. Robert W. Baird upped their target price on shares of LivaNova from $66.00 to $72.00 and gave the company an “outperform” rating in a research note on Thursday, October 31st. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $75.00 price target on shares of LivaNova in a report on Monday, November 25th. One analyst has rated the stock with a hold rating, five have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $69.17.

LivaNova Stock Down 0.4 %

LivaNova stock opened at $49.94 on Tuesday. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.87 and a current ratio of 3.37. LivaNova has a one year low of $43.15 and a one year high of $64.47. The company has a 50-day simple moving average of $51.88 and a 200-day simple moving average of $51.27. The firm has a market capitalization of $2.71 billion, a P/E ratio of 118.90 and a beta of 0.98.

Insider Buying and Selling at LivaNova

In related news, Director Francesco Bianchi sold 1,250 shares of the firm’s stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $50.99, for a total transaction of $63,737.50. Following the transaction, the director now directly owns 7,522 shares in the company, valued at $383,546.78. This trade represents a 14.25 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 0.27% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in LIVN. Fifth Third Bancorp boosted its position in shares of LivaNova by 97.1% during the second quarter. Fifth Third Bancorp now owns 674 shares of the company’s stock valued at $37,000 after buying an additional 332 shares during the last quarter. Canada Pension Plan Investment Board bought a new stake in LivaNova during the 2nd quarter valued at approximately $88,000. Central Pacific Bank Trust Division purchased a new stake in LivaNova in the 3rd quarter worth $178,000. TradeLink Capital LLC bought a new stake in shares of LivaNova in the second quarter worth about $208,000. Finally, Captrust Financial Advisors bought a new stake in LivaNova in the third quarter worth $217,000. 97.64% of the stock is owned by hedge funds and other institutional investors.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.